You now have extra time to finalize your proposal, as the submission deadline has been officially extended to April 23, 2026. Please note a newly added timeline requirement: if selected, your project must have an executed agreement and all necessary regulatory approvals finalized by November 1, 2026.
Funder: Pfizer Inc.
Due Dates: April 9, 2026 (original) | April 23, 2026 (extended)
Funding Amounts: Up to EUR 40,000 per project (max 18 months); total RFP budget EUR 140,000.
Summary: Supports quality improvement projects to enhance non-pharmacological management of ALK TKI adverse events and quality of life for ALK+ NSCLC patients in Spain.
Key Information: Only organizations in Spain are eligible; late applications will not be reviewed.